CoChat

Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study

Open access
Ferguson, Campieri, Doe, Persson, Nygård, THE GLOBAL BUDESONIDE STUDY GROUP · 1998 · Alimentary Pharmacology & Therapeutics
Cited by 125

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Budesonide is a corticosteroid with high topical anti‐inflammatory activity and low systemic activity due to rapid inactivation. We have assessed the efficacy and safety of an oral controlled ileal release (CIR) preparation of budesonide for maintenance of remission in patients with ileal or ileocaecal Crohn’s disease. Methods: In a double‐blind, multicentre trial, 75 patients in clinical remission (Crohn’s Disease Activity Index, CDAI, ≤ 150) were randomly assigned to receive placebo, budesonide 3 mg or budesonide 6 mg daily for 12 months. Trial drugs were given at a fixed dose and without concomitant medication. The primary outcome measure was relapse, defined as a CDAI > 150 together with an increase of at least 60 units from entry. A patient was also considered to have a relapse if withdrawn from the study due to clinical deterioration, whether or not a CDAI value could be calculated at that time. Results: There were no statistically significant differences in the relapse rate at any time‐point throughout the study. By 12 months the proportion of patients having relapsed were 48, 46 and 60% in those patients treated with budesonide 6 mg, 3 mg and placebo, respectively (N.S.). Treatments were well tolerated, and the proportion of patients with suppressed adrenal function (according to predetermined criteria) were 50% (6 mg), 26% (3 mg) and 17% (placebo) (P = 0.096). Conclusions: In the present study, relapse rate and time to relapse were similar in the patients treated with budesonide CIR, 6 mg daily or 3 mg daily or with placebo, throughout 12 months. This is in contrast to the two previous trials with identical design, where a significant effect of budesonide CIR in prolonging the median time to relapse was found. Possible reasons for the negative results of the present study include small sample size, and the fact that there was a high placebo response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.1998.00285.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 125

Metadata

Authors
Ferguson, Campieri, Doe, Persson, Nygård, & THE GLOBAL BUDESONIDE STUDY GROUP
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
1998-02
Volume
12
Issue
2
Pages
175-183
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1970895990
Cited by
125
References
2
FWCI
4.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study. https://app.cochat.ai/papers/10.1046/j.1365-2036.1998.00285.x
The paper
Ferguson, Campieri, Doe, Persson, Nygård, & THE GLOBAL BUDESONIDE STUDY GROUP. (1998). Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1998.00285.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.